Top stocks to watch on August 11: Tata Motors, Dr. Reddy's Laboratories, IDFC First Bank, Zydus and more
Several companies are in focus today, Monday, August 11, following notable earnings reports, regulatory approvals, and other corporate developments. Stocks To Watch Today
Oil Marketing Companies (OMCs): The government has approved ₹30,000 crore as compensation for LPG under-recoveries.
Dr. Reddy's Laboratories (DRL): The US FDA has issued an Establishment Inspection Report (EIR) for its CTO-5 manufacturing unit in Telangana, classifying it as 'Voluntary Action Indicated' (VAI).
DOMS Industries: Q1 revenue rose 26% year-on-year (YoY), while EBITDA increased 14% YoY.
Lemon Tree Hotels: Average room rate increased 10% YoY, with EBITDA margin at 44.5% compared to 43% last year.
Power Mech Projects: EBITDA rose 49% YoY, margin improved to 13.2% from 11.3% a year ago.
Entero Healthcare: EBITDA increased 63% YoY, margin at 3.5% compared to 2.8% last year.
DCW Ltd: EBITDA grew 18.4% YoY, margin improved to 11.4% from 9% last year.
IDFC First Bank: Platinum Invictus B 2025 RSC received RBI approval for its proposed investment in the bank.
Brigade Enterprises: Launched 'Brigade Cherry Blossom' project in East Bengaluru, with revenue potential of ₹225 crore.
Shilpa Medicare: Received CDSCO approval for NorUDCA tablets, used in treatment of non-alcoholic fatty liver disease.
Zydus Lifesciences: Received final US FDA approval for Prucalopride tablets.
BEML: Secured its first overseas contract from Malaysia worth $1 million.
NIBE Ltd: Won export order from Israel for ship-mounted universal rocket launching systems.
ICICI Bank: Increased minimum balance requirement for new accounts effective August 1.
Tata Motors: Reported mixed Q1 results against muted estimates; volumes declined across categories.
Siemens: Q3FY25 EBITDA margin came in lower than estimates, net profit 7% below expectations.
Manappuram Finance: Q1 results below estimates; calculated NIM fell 80 bps quarter-on-quarter.
Home First Finance: Range Clove likely to sell its entire 10.3% equity stake via block deals at a 0-5% discount to CMP.
Voltas: Q1 results below estimates; margin declined to 4.5% from 8.6% YoY.
Ceigall India: EBITDA fell 24% YoY, margin down to 13% from 17.4%.
Dhampur Sugar: EBITDA declined 16.5% YoY, margin at 3% versus 4% last year.
Shipping Corporation of India: EBITDA fell 4% YoY, revenue down 13%.
Puravankara: Reported a net loss compared to profit last year; revenue fell 20% YoY.
TVS Supply Chain Solutions: EBITDA declined 2.2% YoY, margin at 6.83% versus 7.12%.
Suprajit Engineering: Margin fell to 9.47% from 11.74% last year; EBITDA declined 5.3% YoY.
Ahmedabad Plane Crash Dr Reddy's LaboratoriesIDFC First BankTata MotorsZydus
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202 Product Candidate Using AAVnerGene's Platform Technology
NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), announces that it signed a binding agreement to initiate manufacturing and development of its KLTO-202 gene therapy candidate using the AAVnerGene Inc. (AAVnerGene) platform technology. As previously announced, AAVnerGene is an innovation-driven biotech renowned for its transformative technologies in adeno-associated viruses (AAV) manufacturing and tissue-targeted delivery. KLOTHO is a biotechnology company focused on the development of groundbreaking, disease-modifying cell and gene therapies using a human gene and protein derived from its patented form of the "anti-aging" Klotho gene. Dr. Joseph Sinkule, KLOTHO CEO, stated, "The AAVnerGene technology is a game-changer in manufacturing AAV vectors for intracellular delivery of genes. The initiation of manufacturing is a key milestone in the development of any biotech product, and the manufacturing of gene therapy products presents particular complications. KLOTHO is using AAVnerGene's cutting-edge 'AAVone' platform technology and engineered HEK293 cell line to introduce the plasmid DNA containing our Klotho gene, so that the AAV particles containing our gene are at a higher-than-normal titer concentration, have fewer impurities, and can be optimized and produced faster than the old standard method. We believe that working with AAVnerGene as our development partner has the potential to launch our product candidates into the clinic at a faster pace, lower cost, higher efficacy, and higher purity compared to the current 'triple transfection' manufacturing method." One of the major challenges facing AAV-vectored gene therapies is the propensity of the AAVs to home in on the liver and induce an inflammatory response that causes life-threatening side effects and even death. AAVnerGene created a series of specific tissue-targeting AAVs developed with its 'ATHENA' platform technology. Using the ATHENA system and tissue-specific targeting of the KLTO gene therapy product candidates containing KLTO's tissue-specific promoters will be proven to be highly beneficial and likely safer than the AAV vectors that traffic to the liver. AAVnerGene and Complexity of AAV-vectored Cell Lines Over the past 20 years of gene therapy, investigators and companies used a process called "triple transfection" whereby three DNA plasmids are transfected, or inserted, into the cell line called HEK293. The three plasmids contain sequences of the 'gene-of-interest', Rep/Cap sequences from AAV and 'Helper' sequences from Adenovirus to provide essential viral genes to enable replication and packaging of the AAV. As the HEK293 cells replicate and produce the viral proteins, the HEK293 cells assemble the proteins required to make the AAV particles containing the gene-of-interest inside the AAV particle. This is a complicated, tedious, labor-intensive process requiring optimization that may take several months or a year to complete. AAVnerGene developed a one-plasmid AAV packaging system called "AAVone," which dramatically increased the production efficiency, simplified the process, reduced the impurity, shortened the time and lowered the development cost. About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's disease, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. KLOTHO is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization. Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFOir@ About AAVnerGene, Inc. AAVnerGene is a creativity-powered biotechnology company pioneering next-generation AAV vector technologies. The company's proprietary platforms include AAVone, a high-yield, single-plasmid AAV production system that dramatically reduces manufacturing costs, and ATHENA, an advanced capsid engineering platform enabling precise tissue targeting. AAVnerGene is dedicated to delivering affordable, scalable, and precision-engineered gene therapy solutions that accelerate clinical development across diverse therapeutic areas. Investor Contact and Corporate Communications – Daozhan Yu, CEO Forward-Looking Statements: This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. View original content to download multimedia: SOURCE Klotho Neurosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
13 hours ago
- Business Upturn
Nifty top gainers and losers today, August 12: Tech Mahindra, Maruti Suzuki, Hero MotoCorp among top performers
The Indian benchmark indices closed lower today, with the Nifty 50 slipping 0.40% to end at 24,487.40 and the Sensex dropping 0.46% to close at 80,235.59. Despite the overall market weakness, several stocks managed to post notable gains, while others faced significant losses. Here's a look at Nifty top gainers and losers that drove the day's action (as per Trendline) for the day: Among the top gainers on the Nifty, Tech Mahindra was up 2.0% to close at 1,511.2, followed by Maruti Suzuki, which rose 2.0% to 12,847. Hero MotoCorp gained 1.8%, ending at 4,644, while Mahindra & Mahindra advanced 1.6% to 3,236.5. NTPC also saw a rise of 1.2%, closing at 340.1. Other notable gainers included Sun Pharmaceutical (up 1.1% to 1,626.5), Cipla (up 1.1% to 1,521.6), Tata Steel (up 1.0% to 160.2), Coal India (up 0.8% to 385.4), and Oil and Natural Gas, which increased 0.7% to 235.4. On the downside, Bajaj Finance led the losers with a 2.8% decline, closing at 853. Trent fell 1.4% to 5,368, and Hindustan Unilever dropped 1.4% to 2,484. Eternal declined 1.3% to 305.3, while HDFC Bank slipped 1.3% to 1,969.9. Nestle India was down 1.3% at 1,091.1, and Tata Consumer Products fell 1.1% to 1,047.7. Bajaj Auto lost 1.1%, closing at 8,186, followed by ICICI Bank down 1.1% to 1,421.4, and Bharat Electronics which decreased 1.0% to 380.3. Overall, while the market faced pressure on August 12, these top gainers and losers highlighted the mixed investor sentiment across key sectors. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Hero MotocorpMaruti SuzukiTech Mahindra Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
13 hours ago
- Business Upturn
PN Gadgil shares soar 8% as Q1 net profit jumps 96.3% YoY to Rs 69.3 crore, revenue up 2.8%
PN Gadgil Jewellers shares surged nearly 8% in Tuesday's trade after the company reported an impressive set of Q1 results, driven by strong profitability and margin expansion. As of 2:20 PM, the shares were trading 7.42% higher at Rs 589.35. The jewellery retailer posted a net profit of ₹69.3 crore for the quarter ended June 2025, a sharp 96.3% jump from ₹35.3 crore in the same period last year. Revenue grew 2.8% year-on-year to ₹1,714.5 crore from ₹1,668 crore, reflecting steady sales despite a challenging retail environment. Operational performance was also robust, with EBITDA rising 71.5% to ₹109.9 crore compared to ₹64.1 crore last year, while margins improved significantly to 6.4% from 3.8% a year ago, indicating better cost control and higher efficiency. On the market front, the stock opened at ₹551.50 and gained momentum, hitting an intraday high of ₹603.50 against a low of ₹548.00. The counter remains well above its 52-week low of ₹473.80 but is still some distance from its 52-week high of ₹848.00. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
